



# Prior Authorization Request Administrative Information

## Member information

Last name  First name  MI

Member ID  Date of birth

Sex assigned at birth  Female  Male  "X" or Intersex

Current gender  Female  Male  Transgender male  Transgender female  Other

Place of residence  Home  Nursing facility  Other

Race  Ethnicity

Preferred spoken language  Preferred written language

MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).

## Plan contact information

Please indicate the member's MassHealth Plan and fax or submit this completed and signed form according to the Plan's contact information below.

### MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, and Children's Medical Security Plan

**MassHealth Drug Utilization Review Program**  
Pharmacy: Fax: (877) 208-7428 - Tel: (800) 745-7318

### MassHealth Managed Care Organization (MCO) and Accountable Care Partnership Plans (ACPP)

**Fallon Health**  
Online Prior Authorization: [go.covermymeds.com/OptumRx](http://go.covermymeds.com/OptumRx)  
Online Prior Authorization: [providerportal.surescripts.net/ProviderPortal/optum](http://providerportal.surescripts.net/ProviderPortal/optum)  
Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033

**Health New England**  
Online Prior Authorization: [go.covermymeds.com/OptumRx](http://go.covermymeds.com/OptumRx)  
Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545

**Mass General Brigham Health Plan**  
Online Prior Authorization (Pharmacy Benefit Reviews): [go.covermymeds.com/OptumRx](http://go.covermymeds.com/OptumRx)  
Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555  
Online Prior Authorization (Medical Specialty Reviews): [provider.massgeneralbrighamhealthplan.org](http://provider.massgeneralbrighamhealthplan.org)  
Medical Specialty Reviews: Fax: (888) 656-6671 - Tel: (833) 895-2611

**Tufts Health Plan**  
Online Prior Authorization: [point32health.promptpa.com](http://point32health.promptpa.com)  
Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985

**WellSense Health Plan**  
Online Prior Authorization: [wellsense.org/providers/ma/pharmacy/prior-authorizations](http://wellsense.org/providers/ma/pharmacy/prior-authorizations)  
Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822

# Glaucoma Agents Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at [www.mass.gov/druglist](http://www.mass.gov/druglist).

## Medication information

**Medication requested** (Where applicable, the brand name is provided in brackets for reference.)

- |   |  |
|---|--|
| <input type="checkbox"/> bimatoprost 0.03% ophthalmic solution                    | <input type="checkbox"/> tafluprost                              |
| <input type="checkbox"/> dorzolamide/timolol preservative free                    | <input type="checkbox"/> timolol [Betimol]                       |
| <input type="checkbox"/> Durysta (bimatoprost implant) <sup>MB</sup>              | <input type="checkbox"/> timolol ophthalmic gel forming solution |
| <input type="checkbox"/> Idose TR (travoprost intracameral implant) <sup>MB</sup> | <input type="checkbox"/> timolol ophthalmic unit dose solution   |
| <input type="checkbox"/> Iyuzeh (latanoprost solution)                            | <input type="checkbox"/> Vyzulta (latanoprostene)                |
| <input type="checkbox"/> Rhopressa (netarsudil)                                   | <input type="checkbox"/> Xelpros (latanoprost emulsion)          |
| <input type="checkbox"/> Rocklatan (netarsudil/latanoprost)                       |  |

<sup>MB</sup> This drug is available through the health care professional who administers the drug or in an outpatient or inpatient hospital setting. MassHealth does not pay for this drug to be dispensed through the retail pharmacy. If listed, PA does not apply through the acute hospital inpatient setting, unless on the APAD/APEC carve-out drug list, or in the emergency, trauma, or urgent acute hospital outpatient settings. Please refer to 130 CMR 433.408 for PA requirements for other health care professionals. Notwithstanding the above, this drug may be an exception to the unified pharmacy policy; please refer to respective MassHealth Accountable Care Partnership Plans (ACPPs) and Managed Care Organizations (MCOs) for PA status and criteria, if applicable.

**Indication** (Check all that apply or include ICD-10 code, if applicable.)

- Open-angle glaucoma       Ocular hypertension       Other

**Dose, frequency, and duration of medication requested**

Drug NDC (if known) or service code

## Section I. Please complete for timolol [Betimol], timolol ophthalmic gel forming solution and timolol ophthalmic unit dose solution requests.

Has the member had a trial with an ophthalmic timolol formulation that is available without PA?

- Yes  No. Please provide clinical rationale for not using an ophthalmic timolol formulation that is available without PA.

## Section II. Please complete for bimatoprost 0.03% requests.

1. Has the member had a trial with latanoprost solution or travoprost 0.004% eye drop?

- Yes. Please list the drug name, dates/duration of use, and outcomes below.

Drug name  Dates/duration

Did the member experience any of the following?  Adverse reaction  Inadequate response  Other  
Briefly describe details of adverse reaction, inadequate response, or other.

Drug name  Dates/duration

Did the member experience any of the following?  Adverse reaction  Inadequate response  Other  
Briefly describe details of adverse reaction, inadequate response, or other.

  

No. Please provide clinical rationale for not using latanoprost solution and travoprost 0.004% eye drops.

2. Has the member had a trial with Lumigan?

Yes. Please list the dates/duration of use and outcomes below.

Dates/duration   Adverse reaction  Inadequate response  Other  
Briefly describe details of adverse reaction, inadequate response, or other.

No. Please provide clinical rationale for not using Lumigan.

  

---

### Section III. Please complete for Durysta requests.

1. Has the member had a trial with Lumigan?

Yes. Please list the dates/duration of use and outcomes below.

Dates/duration   Adverse reaction  Inadequate response  Other  
Briefly describe details of adverse reaction, inadequate response, or other.

No. Please describe medical necessity for an implantable formulation instead of eye drops.

  

2. Please specify affected eye.  Left eye  Right eye

3. Is the request for retreatment of the same eye?  Yes  No

---

### Section IV. Please complete for dorzolamide/timolol preservative free and Xelpros requests.

Has the member experienced sensitivity to benzalkonium chloride or any other preservatives used in ophthalmic preparations?

Yes  No. Please provide clinical rationale for the use of the requested formulation instead of the respective formulation that is available without PA.

---

### Section V. Please complete for Rhopressa and Rocklatan requests.

1. Has the member had a trial of combination therapy with a prostaglandin analog and an ophthalmic beta-blocker?

Yes. Please list the drug names, dates/duration of use and outcomes below.\*

No. Please provide clinical rationale for not using combination therapy with a prostaglandin analog and an ophthalmic beta-blocker.

2. Does the member have a contraindication to ophthalmic beta-blockers?

Yes. Please describe.   No

If yes, has the member had a trial of combination therapy with a prostaglandin analog and either an ophthalmic alpha-2 adrenergic agonist, parasympathomimetic, or carbonic anhydrase inhibitor?

Yes. Please list the drug names, dates/duration of use and outcomes below.\*  No

3. For Rhopressa, does the member have a contraindication to prostaglandin analogs?

Yes. Please describe.  No

If yes, has the member had a trial of combination therapy with an ophthalmic beta-blocker and either an ophthalmic alpha-2 adrenergic agonist, parasympathomimetic, or carbonic anhydrase inhibitor?

Yes. Please list the drug names, dates/duration of use and outcomes below.\*  No

Please provide details for the previous trials.

Drug  Dates/duration   Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

Drug  Dates/duration   Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

*\*Please attach a letter documenting additional trials as necessary.*

---

### Section VI. Please complete for Vyzulta requests.

Has the member had an inadequate response to a trial of combination therapy with latanoprost solution and an ophthalmic beta-blocker?  Yes  No.

If no, has the member had a trial with latanoprost solution?

Yes. Please list the dates/duration of use and outcomes below.

Dates/duration  Outcome

If no, has the member had an adverse reaction to an ophthalmic beta-blocker?

Yes. Please list the dates/duration of use and outcomes below.

Dates/duration  Outcome

No. Please provide clinical rationale for not using ophthalmic beta-blocker.

---

### Section VII. Please complete for Iyuzeh and tafluprost requests.

1. Has the member had a trial with latanoprost solution available without PA?

Yes. Please list the dates/duration of use and outcomes below.

Dates/duration   Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

No. Please provide clinical rationale for not using latanoprost solution available without PA.

2. Has the member had a trial with Xelpros?

Yes. Please list the dates/duration of use and outcomes below.

Dates/duration   Adverse reaction  Inadequate response  Other

Briefly describe details of adverse reaction, inadequate response, or other.

No. Please provide clinical rationale for not using Xelpros.

---

**Section VIII. Please complete for Idose TR.**

1. Have the affected eye(s) been previously treated with IdoseTR?  Yes  No
2. Has the member had a trial with travoprost 0.004% ophthalmic solution?  
 Yes. Please list the dates/duration of use and outcomes below.

Dates/duration   Adverse reaction  Inadequate response  Other  
Briefly describe details of adverse reaction, inadequate response, or other.

- No. Please describe medical necessity for an implantable formulation instead of eye drops.

---

**Section IX. Please complete and provide documentation for exceptions to step therapy.**

1. Is the alternative drug required under the step therapy protocol contraindicated, or will likely cause an adverse reaction in, or physical or mental harm to, the member?  Yes  No

If yes, briefly describe details of contraindication, adverse reaction, or harm.

2. Is the alternative drug required under the step therapy protocol expected to be ineffective based on the known clinical characteristics of the member and the known characteristics of the alternative drug regimen?

Yes  No

If yes, briefly describe details of known clinical characteristics of member and alternative drug regimen.

3. Has the member previously tried the alternative drug required under the step therapy protocol, or another alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?

Yes  No

If yes, please provide details for the previous trial.

Drug name  Dates/duration of use

Did the member experience any of the following?  Adverse reaction  Inadequate response

Briefly describe details of adverse reaction or inadequate response.

4. Is the member stable on the requested prescription drug prescribed by the health care provider, and switching drugs will likely cause an adverse reaction in, or physical or mental harm to, the member?

Yes. Please provide details.

No

---

**Please continue to next page and complete Prescriber and Provider Information section.**

# Prior Authorization Request Prescriber and Provider Information

## Prescriber information

Last name*	<input type="text"/>	First name*	<input type="text"/>	MI	<input type="text"/>
NPI*	<input type="text"/>	Individual MH Provider ID	<input type="text"/>		
DEA No.	<input type="text"/>	Office Contact Name	<input type="text"/>		
Address	<input type="text"/>	City	<input type="text"/>	State	<input type="text"/>
		Zip	<input type="text"/>		
E-mail address	<input type="text"/>				
Telephone No.*	<input type="text"/>				
Fax No.* (Please provide fax number for PA response notification.)	<input type="text"/>				

\* Required

## Please also complete for professionally administered medications, if applicable.

Start date	<input type="text"/>	End date	<input type="text"/>		
Servicing prescriber/facility name	<input type="text"/>	<input type="checkbox"/>	Same as prescribing provider		
Servicing provider/facility address	<input type="text"/>				
Servicing provider NPI/tax ID No.	<input type="text"/>				
Name of billing provider	<input type="text"/>				
Billing provider NPI No.	<input type="text"/>				
Is this a request for recertification?	<input type="checkbox"/>	Yes	<input type="checkbox"/>	No	
CPT code	<input type="text"/>	No. of visits	<input type="text"/>	J code	<input type="text"/>
				No. of units	<input type="text"/>

## Provider's attestation, signature, and date

I certify under the pains and penalties of perjury that I am either the prescribing provider or duly authorized to act on behalf of the provider identified in the Prescriber information section of this form. Any attached statement on letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

### Signature of provider or individual duly authorized to act on behalf of the provider:

Printed legal name and title of signatory above

<input type="text"/>	Date	<input type="text"/>
----------------------	------	----------------------

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)